Jianliang Shen
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Jianliang Shen has a total of 22 co-authors. Here are the top co-authors by number of shared publications:
- Andrew J. Gow
Rutgers University
2 shared publications - Debra L. Laskin
Department of Pharmacology and Toxicology, Ernest Mario School of Pharmacy, Rutgers University , Piscataway, NJ 08854
2 shared publications - Jeffrey D. Laskin
Department of Environmental and Occupational Health and Justice, Rutgers University School of Public Health, Piscataway, NJ, USA
2 shared publications - Kinal Patel-Vayas
Department of Pharmacology and Toxicology, Rutgers University, Ernest Mario School of Pharmacy, Piscataway, NJ, United States
2 shared publications - Vasanthi R. Sunil
Department of Pharmacology and Toxicology, Rutgers University, Piscataway, NJ 08854, USA
2 shared publications - Alex J. Bott
Department of Chemical Biology, Ernest Mario School of Pharmacy, Rutgers-The State University of New Jersey, Piscataway, New Jersey, USA
1 shared publication
Latest Publications
- Open Access
- 15 December 2022
- Published by American Society for Clinical Investigation in Journal of Clinical Investigation
- Vol. 132 (24)
Glutamine synthetase limits β-catenin–mutated liver cancer growth by maintaining nitrogen homeostasis and suppressing mTORC1
Glutamine synthetase (GS) catalyzes de novo synthesis of glutamine that facilitates cancer cell growth. In the liver, GS functions next to the urea cycle to remove ammonia waste. As a dysregulated urea cycle is implicated in cancer development, the impact of GS’s ammonia clearance function has not been explored in cancer. Here, we show that oncogenic activation of β-catenin (encoded by CTNNB1) led to a decreased urea cycle and elevated ammonia waste burden. While β-catenin induced the expression of GS, which is thought to be cancer promoting, surprisingly, genetic ablation of hepatic GS accelerated the onset of liver tumors in several mouse models that involved β-catenin activation. Mechanistically, GS ablation exacerbated hyperammonemia and facilitated the production of glutamate-derived nonessential amino acids, which subsequently stimulated mechanistic target of rapamycin complex 1 (mTORC1). Pharmacological and genetic inhibition of mTORC1 and glutamic transaminases suppressed tumorigenesis facilitated by GS ablation. While patients with hepatocellular carcinoma, especially those with CTNNB1 mutations, have an overall defective urea cycle and increased expression of GS, there exists a subset of patients with low GS expression that is associated with mTORC1 hyperactivation. Therefore, GS-mediated ammonia clearance serves as a tumor-suppressing mechanism in livers that harbor β-catenin activation mutations and a compromised urea cycle.
- 15 December 2022
- Published by American Society for Clinical Investigation in Journal of Clinical Investigation
- Vol. 132 (24)
Open AccessGlutamine synthetase limits β-catenin–mutated liver cancer growth by maintaining nitrogen homeostasis and suppressing mTORC1
Glutamine synthetase (GS) catalyzes de novo synthesis of glutamine that facilitates cancer cell growth. In the liver, GS functions next to the urea cycle to remove ammonia waste. As a dysregulated urea cycle is implicated in cancer development, the impact of GS’s ammonia clearance function has not been explored in cancer. Here, we show that oncogenic activation of β-catenin (encoded by CTNNB1) led to a decreased urea cycle and elevated ammonia waste burden. While β-catenin induced the expression of GS, which is thought to be cancer promoting, surprisingly, genetic ablation of hepatic GS accelerated the onset of liver tumors in several mouse models that involved β-catenin activation. Mechanistically, GS ablation exacerbated hyperammonemia and facilitated the production of glutamate-derived nonessential amino acids, which subsequently stimulated mechanistic target of rapamycin complex 1 (mTORC1). Pharmacological and genetic inhibition of mTORC1 and glutamic transaminases suppressed tumorigenesis facilitated by GS ablation. While patients with hepatocellular carcinoma, especially those with CTNNB1 mutations, have an overall defective urea cycle and increased expression of GS, there exists a subset of patients with low GS expression that is associated with mTORC1 hyperactivation. Therefore, GS-mediated ammonia clearance serves as a tumor-suppressing mechanism in livers that harbor β-catenin activation mutations and a compromised urea cycle.
- 1 February 2011
- Published by Elsevier in Toxicology and Applied Pharmacology
- Vol. 250 (3) , 245-255
Role of TNFR1 in lung injury and altered lung function induced by the model sulfur mustard vesicant, 2-chloroethyl ethyl sulfide
- 1 February 2011
- Published by Elsevier in Toxicology and Applied Pharmacology
- Vol. 250 (3) , 245-255
Role of TNFR1 in lung injury and altered lung function induced by the model sulfur mustard vesicant, 2-chloroethyl ethyl sulfide
- 1 January 2011
- Published by Elsevier in Toxicology and Applied Pharmacology
- Vol. 250 (1) , 10-18
Functional and inflammatory alterations in the lung following exposure of rats to nitrogen mustard
- 1 January 2011
- Published by Elsevier in Toxicology and Applied Pharmacology
- Vol. 250 (1) , 10-18
Functional and inflammatory alterations in the lung following exposure of rats to nitrogen mustard